Osteosarcoma: Diagnostic dilemmas in histopathology and prognostic factors
- PMID: 24932029
- PMCID: PMC4052022
- DOI: 10.4103/0019-5413.132497
Osteosarcoma: Diagnostic dilemmas in histopathology and prognostic factors
Abstract
Osteosarcoma (OS), the commonest malignancy of osteoarticular origin, is a very aggressive neoplasm. Divergent histologic differentiation is common in OS; hence triple diagnostic approach is essential in all cases. 20% cases are atypical owing to lack of concurrence among clinicoradiologic and pathologic features necessitating resampling. Recognition of specific anatomic and histologic variants is essential in view of better outcome. Traditional prognostic factors of OS do stratify patients for short term outcome, but often fail to predict their long term outcome. Considering the negligible improvement in the patient outcome during the last 20 years, search for novel prognostic factors is in progress like ezrin vascular endothelial growth factor, chemokine receptors, dysregulation of various micro ribonucleic acid are potentially promising. Their utility needs to be validated by long term followup studies before they are incorporated in routine clinical practice.
Keywords: Osteosarcoma; ezrin; prognostic factors; vascular endothelial growth factor.
Conflict of interest statement
Similar articles
-
Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways.Mol Cancer. 2009 Dec 10;8:118. doi: 10.1186/1476-4598-8-118. Mol Cancer. 2009. PMID: 20003259 Free PMC article.
-
A humanized bone microenvironment uncovers HIF2 alpha as a latent marker for osteosarcoma.Acta Biomater. 2019 Apr 15;89:372-381. doi: 10.1016/j.actbio.2019.02.051. Epub 2019 Mar 2. Acta Biomater. 2019. PMID: 30836200
-
Ezrin expression predicts survival in stage IIB osteosarcomas.Clin Orthop Relat Res. 2007 Jun;459:229-36. doi: 10.1097/BLO.0b013e3180413dbf. Clin Orthop Relat Res. 2007. PMID: 17353802
-
The Prognostic Role of Ezrin Immunoexpression in Osteosarcoma: A Meta-Analysis of Published Data.PLoS One. 2013 Jun 21;8(6):e64513. doi: 10.1371/journal.pone.0064513. Print 2013. PLoS One. 2013. PMID: 23805177 Free PMC article. Review.
-
Prognostic factor studies in oncology: osteosarcoma as a clinical example.Int J Radiat Oncol Biol Phys. 2001 Feb 1;49(2):513-8. doi: 10.1016/s0360-3016(00)01507-8. Int J Radiat Oncol Biol Phys. 2001. PMID: 11173148 Review.
Cited by
-
MiRNA encoded PTEN's impact on clinical-pathological features and prognosis in osteosarcoma: A systematic review and meta-analysis.PLoS One. 2024 Sep 19;19(9):e0304543. doi: 10.1371/journal.pone.0304543. eCollection 2024. PLoS One. 2024. PMID: 39298504 Free PMC article.
-
CCCTC-binding factor regulates splicing factor proline and glutamine-rich to promote malignant growth of osteosarcoma.Am J Transl Res. 2025 Feb 25;17(2):1495-1509. doi: 10.62347/STQK5435. eCollection 2025. Am J Transl Res. 2025. PMID: 40092088 Free PMC article.
-
Osteosarcoma of jaws: Challenges in diagnosis.J Oral Maxillofac Pathol. 2020 Sep-Dec;24(3):589. doi: 10.4103/jomfp.JOMFP_142_20. Epub 2021 Jan 9. J Oral Maxillofac Pathol. 2020. PMID: 33967520 Free PMC article.
-
Comparative Shotgun Proteomics Reveals the Characteristic Protein Signature of Osteosarcoma Subtypes.Cells. 2023 Aug 30;12(17):2179. doi: 10.3390/cells12172179. Cells. 2023. PMID: 37681913 Free PMC article.
-
Special AT-rich sequence-binding protein 2 (SATB2) in the differential diagnosis of osteogenic and non-osteogenic bone and soft tissue tumors.J Pathol Transl Med. 2022 Sep;56(5):270-280. doi: 10.4132/jptm.2022.07.11. Epub 2022 Sep 13. J Pathol Transl Med. 2022. PMID: 36128863 Free PMC article.
References
-
- Mirra JM, Gold RH, Picci P. Osseous tumors of intranedullary origin. In: Mirra JM, Picci P, Gold RH, editors. Bone Tumors. Clinical, Radiologic and Pathologic Correlations. Philadelphia: Lea and Febiger Publishers; 1989. pp. 143–438.
-
- Fechner RE, Mills SE. Tumors of the Bones and Joints. Washington DC: Armed Forces Institute of Pathology; 1992. Atlas of Tumor Pathology.
-
- Bacci G, Longhi A, Versari M, Mercuri M, Briccoli A, Picci P. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer. 2006;106:1154–61. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources